Amphastar Pharmaceutical Q4 Earnings Preview

Amphastar Pharmaceutical AMPH announces its next round of earnings Monday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.

Earnings and Revenue

Wall Street expects EPS loss of 2 cents and sales around $60.6 million.

In the same quarter last year, Amphastar Pharmaceutical reported EPS of 1 cent on revenue of $63.5 million. If the company were to match the consensus estimate when it reports Monday, EPS would have fallen 300 percent. Sales would be down 4.6 percent on a year-over-year basis.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:

Stock Performance

Over the last 52-week period, shares are up 30.74 percent. Given that these returns are generally positive, long-term shareholders are probably content going into this earnings release. Analyst estimates are adjusted lower for EPS and revenues over the past 90 days. The popular rating by analysts on Amphastar Pharmaceutical stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

Amphastar Pharmaceutical's Q4 conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here: http://ir.amphastar.com/events-and-presentations